Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2018 04:00 ET | Source: AC Immune SA

AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease

Tau small molecules (Tau Morphomers) demonstrate target-specific reduction of pathological Tau as well as cognitive and functional improvement Significant reduction of microglia activation...
March 20, 2018 05:00 ET | Source: AC Immune SA

AC Immune reports full-year 2017 financial results - successful first year as a public company

Lausanne, Switzerland, March 20, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
March 15, 2018 05:00 ET | Source: AC Immune SA

AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease

First potential PET tracer for Parkinson's disease First in human study is scheduled for the second half of 2018 AC Immune's lead compound is highly selective for alpha-synuclein - a key protein...
February 06, 2018 08:30 ET | Source: AC Immune SA

AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference

Lausanne, Switzerland, - February 6, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
December 01, 2017 14:20 ET | Source: AC Immune SA

AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Lausanne, Switzerland, December 1, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, shared...
November 21, 2017 08:31 ET | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases

Lausanne, Switzerland, November 21, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
November 13, 2017 06:47 ET | Source: AC Immune SA

AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update

Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults...
November 02, 2017 06:22 ET | Source: AC Immune SA

AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease

AC Immune to receive third milestone payment of CHF 14 million under collaboration agreement with Genentech Phase 2 to evaluate effects of anti-Tau antibody in...
October 24, 2017 05:40 ET | Source: AC Immune SA

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference

AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference Lausanne, Switzerland, - October 24, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based,...
October 03, 2017 04:53 ET | Source: AC Immune SA

AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research

Continued development of PET tracer for earlier and more accurate diagnosis of Parkinson's disease Focuses on alpha-synuclein, a key protein in Parkinson's disease pathology Lausanne,...